Novavax Inc (NVAX)vsVertex Pharmaceuticals Inc (VRTX)
NVAX
Novavax Inc
$9.34
+0.86%
HEALTHCARE · Cap: $1.52B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 968% more annual revenue ($12.00B vs $1.12B). NVAX leads profitability with a 39.2% profit margin vs 32.9%. NVAX appears more attractively valued with a PEG of 1.32. VRTX earns a higher WallStSmart Score of 66/100 (B-).
NVAX
Buy56
out of 100
Grade: C
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+48.9%
Fair Value
$17.54
Current Price
$9.34
$8.20 discount
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Keeps 39 of every $100 in revenue as profit
Revenue surging 66.6% year-over-year
Conservative balance sheet, low leverage
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
ROE of -898.0% — below average capital efficiency
Earnings declined 38.1%
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVAX
The strongest argument for NVAX centers on P/E Ratio, Profit Margin, Revenue Growth. Profitability is solid with margins at 39.2% and operating margin at 14.2%. Revenue growth of 66.6% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : NVAX
The primary concerns for NVAX are Market Cap, Return on Equity, EPS Growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
NVAX profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
NVAX carries more volatility with a beta of 2.63 — expect wider price swings.
NVAX is growing revenue faster at 66.6% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 56/100), backed by strong 32.9% margins. NVAX offers better value entry with a 48.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novavax Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?